Safety and efficacy of twice daily administration of KPI-121 1 for ocular inflammation and pain following cataract surgery

机译：白内障手术后每日两次KPI-121 1％预防眼部炎症和疼痛的安全性和有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeKPI-121 is a nanoparticle suspension of loteprednol etabonate with improved ocular pharmacokinetics compared with marketed formulations. The efficacy and safety of KPI-121 1% ophthalmic suspension (INVELTYS™) dosed twice daily (BID) were evaluated in participants who had undergone cataract surgery.

机译：用途KPI-121是一种洛替泼诺依他宝酯的纳米颗粒悬浮液，与市售制剂相比具有改善的眼药代动力学。每天接受两次白内障手术的参与者评估KPI-121 1％眼部悬浮液（INVELTYS™）的疗效和安全性。

著录项

期刊名称 Clinical Ophthalmology (Auckland N.Z.)
作者
Terry Kim; Kenneth Sall; Edward J Holland; R Kim Brazzell; Susan Coultas; Preeya K Gupta;
展开▼
作者单位

展开▼
年(卷),期 2019(13),-1
年度 2019
页码 69–86
总页数 18
原文格式 PDF
正文语种
中图分类眼科学;
关键词
loteprednol etabonate nanoparticle mucus penetrating particles postoperative ocular inflammation pain;

机译：依托泊洛替诺尔;纳米颗粒;粘液穿透颗粒;术后眼部炎症;疼痛;
入库时间 2022-08-17 13:03:44

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [J] . Terry Kim, Kenneth Sall, Edward J Holland, Clinical ophthalmology . 2018,第10期

机译：白内障手术后每日两次给予KPI-121 1％用于眼部炎症和疼痛的安全性和有效性
2. Results of a Phase 3, Randomized, Double-Masked, Vehicle Controlled Study (Phase 3c) Evaluating the Safety and Efficacy of DEXTENZA (TM) (dexamethasone insert) 0.4 mg for the Treatment of Ocular Inflammation and Pain after Cataract Surgery [J] . Talamo Jonathan H., Tyson Sydney L., Bafna Shamik, Investigative ophthalmology & visual science . 2017,第8期

机译：结果3，随机，双掩盖，车辆控制研究（第3C相）评估Dextenza（TM）（地塞米松插入物）0.4mg的安全性和功效，用于治疗白内障手术后眼睑炎症和疼痛
3. Results of a Phase 3, Randomized, Double-Masked, Vehicle Controlled Study (Phase 3c) Evaluating the Safety and Efficacy of DEXTENZA (TM) (dexamethasone insert) 0.4 mg for the Treatment of Ocular Inflammation and Pain after Cataract Surgery [J] . Talamo Jonathan H., Tyson Sydney L., Bafna Shamik, Investigative ophthalmology & visual science . 2017,第8期

机译：结果3，随机，双掩盖，车辆控制研究（第3C相）评估Dextenza（TM）（地塞米松插入物）0.4mg的安全性和功效，用于治疗白内障手术后眼睑炎症和疼痛
4. Ocular safety limits for 1030 nm femtosecond laser cataract surgery [C] . Jenny Wang, Christopher Sramek, Yannis M. Paulus, Ophthalmic technology XXIII . 2013

机译：1030 nm飞秒激光白内障手术的眼部安全极限
5. PRESURGICAL ANXIETY AND POSTSURGICAL PAIN AND ADJUSTMENT: EFFECTS OF A STRESS INOCULATION PROCEDURE (BEHAVIORAL MEDICINE, SURGERY, HOSPITALIZATION, SELF-EFFICACY, RECOVERY) [D] . WELLS DE VARGAS, JUDITH KAY 1985

机译：术前焦虑和术后疼痛与调整：压力接种程序（行为医学，手术，住院，自我效能感，恢复）的影响
6. Difluprednate ophthalmic emulsion 0.05 (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery [O] . Stephen Smith, Douglas Lorenz, James Peace, 2010

机译：每天两次给予0.05％的双氟泼特钠眼用乳剂（Durezol®）用于治疗白内障手术后的眼部炎症和疼痛
7. Safety and efficacy of twice daily administration of KPI-121 1 for ocular inflammation and pain following cataract surgery [O] . Terry Kim, Kenneth Sall, Edward Holland, 2018

机译：每日两次施用KPI-121 1％的安全性和疗效，对白内障手术后眼镜炎症和疼痛

Safety and efficacy of twice daily administration of KPI-121 1 for ocular inflammation and pain following cataract surgery

摘要

著录项

相似文献

相关主题

期刊订阅